FIELD: biotechnology, genetic engineering, molecular biology, pharmacy. SUBSTANCE: invention relates to new viral vectors. Invention represents the defective recombinant adenoviral vector wherein gene E1 and at least one of genes E2-E4, L1-L5 are non-functional ones. Preferably, vector is prepared from canine adenovirus of serotype CAV1 or CAV2 of the strain Manhattan or A26/61 (ATCC VR-800). Vector is incorporated in pharmaceutical composition useful for genetic therapy. EFFECT: valuable medicinal properties of vector. 30 cl, 10 dwg
Authors
Dates
2003-12-20—Published
1994-07-08—Filed